16 Nov, 2022 Press Releases Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines by curevovaccine
15 Sep, 2022 Press Releases Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles by curevovaccine 4 Comments
10 Feb, 2022 News, Vaccines A small Seattle biotech wants to take on GlaxoSmithKline’s emerging Shingrix blockbuster. RA Capital is on board by curevovaccine
15 Sep, 2020 News, Vaccines Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101 by curevovaccine
